Le traitement per os des troubles de l'érection

Progres en Urologie

Volumn 7, Issue 1, 1997, Pages 108-109

  Giuliano, François ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; APOMORPHINE; CYCLIC GMP; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; PHENTOLAMINE; PIPERAZINE DERIVATIVE; SILDENAFIL; TRAZODONE; YOHIMBINE;

DRUG ANTAGONISM; HUMAN; IMPOTENCE; MALE; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; APOMORPHINE; CYCLIC GMP; DOPAMINE AGONISTS; ENZYME INHIBITORS; HUMANS; IMPOTENCE; MALE; PHENTOLAMINE; PIPERAZINES; TRAZODONE; YOHIMBINE;

EID: 2742561070     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. BALLARD S.A., BURSLEM F.M.F, GINGELL C.J.C., PRICE M.E., TANG K., TURNER L.A., NAYLOR A.M.: In vitro profile of UK92,480, an inhibitor of cyclic GMP-specific phosphodiesterase 5 for the treatment of male erectile dysfunction. J. Urol. 1996, 155, 676 A.
2. BOOLELL M., GEPI-ATTEE S., GINGELL C., ALLEN M.: UK-92,480, a new oral treatment for erectile dysfunction. A doubleblind, placebo controlled crossover study demonstrating dose response with rigiscan and efficacy with outpatient diary. J. Urol.1996, 155, 495 A.
3. DANJOU P., ALEXANDRE L., WAROT D., LACOMBLEZ L., PUECH A.J.: Assessment of erectogenic properties of amorphine and yohimbine in man. Brit. J. Clin. Pharmacol. 1988, 26, 733-739.
4. GINGELL C.J.C., JARDIN A., OLSSON A.M., DINSMORE W.W. OSTERLOH I.H., KIRKPATRICK J., CUDDIGAN M.: UK-92, 480, a new oral treatment for erectile dysfunction: a double blind, placebo-controlled, once daily dose response study. J. Urol., 1996, 155 495a.
5. HEATON J P.W., MORALES A., ADAMS M.A., JOHNSTON B., EL-RASHIDY R.: Recovery of erectile function by the oral administration of apomorphine. Urology, 1995, 45, 200-206
6. JENCK F., MOREAU J.L., MUTEL U., MARTIN J.R., HAEFELY W.E.: Evidence for a role of 5- ht le receptors in the antiserotoninergic properties of some antidepressant drug. Eur. J. Pharmacol. 1993, 231, 223-229.
7. KURT U., OZKARDES H., ALTUG, U., GERMIYA NO GLU C., GURDAL M., EROL D.: The efficacy of anti-serotoninergic agents in the treatment of erectile dysfunction. J. Urol., 1994, 152, 407-409.
8. LAL S., LARYEA E., THAVUNDAYIL J.X., NAIR N.P , NEGRETE J., ACKMAN D., BLUNDELL P., GARDINER R.J.: Apomorphineinduced penile tumescence in impotent patients- preliminary findings. Prog. Neuropsypharmacol Biol. Psychiatry 1987, 11, 235-242.
9. MONTORSI F., STRAMBI L.F., GUAZZONI G., GALLI L., BARBIERI L., RIGATTI P., PIZZINI G., MIANI A.: Effect of yohimbine-trazodone on psychogenic impotence: a randomized double-blind, placebo-controlled study. Urology, 1994, 44, 732-736.
10. MORALES A., HEATON J.P. W., CONDRA M.: The pharmacology of Impotence. In. impotence. Edited by A.H., Bennett. Philadeplphia: W.B. Saunders, 1994, 145-155.
11. REID K., SURRIDGE D.H., MORALES A., CONDRA M., HARRIS C., OWEN J., FENEMORE J. Double blind trial yohimbine in the treatment of psychogenic impotence. Lancet, 1987, 2, 421-423.
12. RILEY A.J., RILEY E.J. Pharmacotherapy for sexual dysfunction: current status In: Sexual Pharmacology. Edited by A.J. RILEY: M. PEET, C. WILSON Oxford Oxford University Press., 1193, 211-226.
13. STIEF C. Communication orale, buccal phentolamine. Society for the study of Impotence, AUA 91st Annual Meeting, Orlando USA, May 4th 1996.
14. WAGNER G., LACY S., LEWIS R., ZORGNIOTTI A. Bucal phentolamine. A pilot trial for male erectile dysfunction at three separate clinics. Int. J. Impotence Res., 1994,6, suppl. 1. D78.
15. ZORGNIOTTI A W. «On demand» oral drug for erection in impotent men. J. Urol , 1192, 147, 308A.